Monitoring and evaluation

A robust monitoring and evaluation (M&E) system is a key component of a strong health system. With the current WHO recommendation of lifelong ART for all pregnant and breastfeeding women living with HIV, outcomes (including maternal survival and final infant HIV status) require monitoring through longitudinal data systems complemented with regular cohort analyses and enhanced monitoring. Additionally, as we move toward the need for more strategic policies and programming to garner system and resource efficiencies, M&E systems need to be designed to be able to inform differences arising from age, sex, and geographic trends as well as identify weaknesses such as sub-optimal commodity supply and testing quality.

Monitoring of individuals on ART is important to ensure treatment efficacy and improved health outcomes. Updated WHO Consolidated ARV Guidelines will be available in December 2015 and include recommendations on routine monitoring and the diagnosis of treatment failure.

In 2015, the IATT monitoring and evaluation working group (MEWG) finalized and disseminated the IATT B+ M&E Framework. One mechanism used to disseminate was to convene a 15 Country Consultation that was determined as follows: the eight 2015 priority countries (Cameroon, Kenya, Mozambique, Nigeria, South Africa, Tanzania, Uganda & Zambia) that contributed 70% of new infections among the Global Plan countries in 2013, three countries (Malawi, Rwanda and Zimbabwe) representing best practices from the region and four countries (Botswana, Cote d’Ivoire, DRC and Namibia) who are in the process of reviewing their M&E systems for B+ roll out.

This report guides countries through the process of collecting and reporting sub-national data on adolescents to inform programme planning and implementation efforts. This guidance has been developed with the specific aim of identifying data gaps for adolescents and informing immediate programme planning needs at the sub-national level.